Morus Alba.
Research-backed compound with potential health benefits. Tree native to China. Leaves traditionally used for blood sugar.
Reviewed March 2026
- Category
- Compound
What Morus Alba is, and what it does.
- Does it work
- Legitimate blood sugar support. Works best alongside diet changes.
- How much to take
- Start with 250 to 1,000mg a day, taken with the first bites of a carbohydrate meal. The extract works in the gut lumen, so timing with food matters as much as the amount.
- Time to feel it
- It acts on the meal in front of you, so its effect on how quickly glucose appears happens inside that same hour. Nothing needs to build up first.
- The first dose
- Often uneventful. After a starchy meal some people notice gas or fullness a few hours later, as spared carbohydrate reaches the colon. That is the mechanism showing up.
- With regular use
- Weeks of daily use with meals show up on post-meal glucose readings more than in how you feel. Gut noise usually settles as your bacteria adapt.
- How well tolerated
- Generally well tolerated. Gas, bloating and looser stools are the common complaints. Talk to your doctor first if you take glucose-lowering medication.
- How it feels
- Mostly unremarkable, apart from a steadier stretch after a big carbohydrate meal instead of the heavy dip some people get. A bit more gas in week one is normal.
- The overlooked benefit
- It can only act on carbohydrate eaten at the same sitting. Taken with a low-carb meal there is almost no substrate for it to work on, so timing is the whole game.
250 to 1,000mg a day is where Morus Alba works.
Source: Kimura et al., Fitoterapia, 2007; Thaipitakwong et al., PLoS ONE, 2018
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Morus Alba is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- alpha-glucosidase inhibition at the brush borderIn vitro study
- post-meal glucose responseRandomised trial
- healthy insulin response after carbohydrateRandomised trial
- blood lipids already in the normal rangeRandomised trial
- flavonol and chlorogenic acid antioxidant capacityIn vitro study
- body weight and compositionRandomised trial
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Mulberry leaf supplies 1-deoxynojirimycin and Salacia supplies salacinol and kotalanol, and all three inhibit intestinal alpha-glucosidase at the brush border. Together they slow the same starch-to-glucose step, so the effect on the post-meal glucose rise is additive.
Mulberry acts in the gut lumen by slowing carbohydrate hydrolysis while corosolic acid acts at the cell by promoting glucose transporter movement to the membrane. The two sit either side of absorption rather than duplicating each other.
Gymnemic acids interfere with sweet taste receptors and with intestinal glucose uptake, while mulberry DNJ blocks the enzymatic release of glucose from starch upstream of that. They cover different points in the same post-meal sequence.
Mulberry limits how fast glucose enters from the lumen and berberine acts inside the cell through AMP-activated protein kinase signalling. Formulas combine them because neither mechanism substitutes for the other.
Cinnamon polyphenols act on insulin receptor signalling downstream of absorption while mulberry limits carbohydrate breakdown in the lumen. The pairing is standard in blends aimed at normal post-meal glucose handling.
Chromium contributes to normal insulin signalling as part of the chromodulin complex, a cofactor role rather than a gut effect. It complements mulberry, which acts entirely in the intestinal lumen.
Viscous konjac fibre slows gastric emptying and forms a diffusion barrier around starch, while mulberry DNJ blocks the alpha-glucosidase step that would release glucose from it. Slowing delivery and slowing hydrolysis stack on the same post-meal curve.
Alpha-glucosidase inhibition pushes undigested carbohydrate further along the gut, where it is fermented, and inulin is itself a fully fermentable substrate. Taken together the gas and bloating load in the colon adds up, which is the usual tolerance limit for both.
Mulberry leaf is rich in flavonoids and chlorogenic-type polyphenols, which form insoluble complexes with non-heme iron in the intestinal lumen. Iron taken in the same dose window is less available as a result.
Mulberry leaf acts in the gut lumen, where 1-deoxynojirimycin competes with dietary oligosaccharides at the brush-border alpha-glucosidases. Alpha-lipoic acid works after absorption, on glucose handling inside the cell. The two sit at different points of the same route, so a formulator can pair them without one blunting the other. No trial has measured the pair together, so read the combination as mechanistic.
Both are carbohydrate-handling botanicals that show up in the same blends. Mulberry leaf slows the enzymatic release of glucose from starch; bitter melon constituents act mainly on post-absorptive glucose uptake. Because the sites differ, the effects are plausibly additive rather than redundant. Anyone already using glucose-lowering medication should have the stack reviewed by their clinician, since additive effects are the point here.
Psyllium raises the viscosity of gut contents, which slows gastric emptying and the rate at which starch reaches the brush border. Mulberry leaf then limits the final hydrolysis step at that border. Slowing delivery and slowing cleavage stack cleanly onto one another. Separate the pair from other supplements by a couple of hours, because viscous fibre delays absorption generally.
Partially hydrolysed guar gum keeps some of the viscosity of the parent gum while staying easier to disperse in a drink. Alongside mulberry leaf it moderates how fast a carbohydrate load presents to the enzyme surface. The pairing is formulation convention in powdered pre-meal blends. It has not been measured as a fixed combination.
Oat beta-glucan is a viscous fibre with a regulatory record for moderating the postprandial glucose rise. Mulberry leaf contributes an enzyme-level brake on the same meal. The mechanisms are independent, so both can operate on one carbohydrate load. Dose beta-glucan high enough to build viscosity or the fibre side contributes little.
Catechins inhibit alpha-amylase and, to a lesser degree, alpha-glucosidase in vitro. Mulberry leaf iminosugars hit alpha-glucosidase specifically and with much higher affinity. Together they cover both the amylase step and the brush-border step of starch breakdown. This is enzyme-level evidence, not a measured human outcome for the pair.
Mulberry leaf already carries quercetin and its glycosides as native constituents, so added quercetin extends a flavonoid profile the extract contains rather than introducing a foreign one. Flavonol glycosides contribute their own weak carbohydrase inhibition alongside the iminosugar fraction. Standardised extracts vary widely in flavonol content, so the added amount is what determines the contribution.
Rutin is quercetin-3-rutinoside and a recognised marker compound in mulberry leaf material. Formulas that add it are topping up a class the leaf already provides. Gut bacteria cleave the sugar before much absorption happens, so the practical exposure is to quercetin either way.
Polyphenols and tannins in leaf material bind divalent minerals in the gut and lower the fraction of zinc taken up. This is the same chelation chemistry that makes tea a poor companion to a mineral tablet. Separating a mulberry leaf dose from a zinc dose by about two hours keeps the interaction out of the way. The direction here is competitive, not supportive.
Ascorbate reduces ferric iron to the ferrous form and keeps it soluble, which partly offsets the mineral binding that plant polyphenols cause at the same meal. Taken with a mulberry leaf preparation it protects non-heme iron uptake rather than adding any glucose-related effect. Read this as an absorption correction, nothing more.
When brush-border hydrolysis is slowed, more carbohydrate reaches the colon and becomes substrate for fermentation. Resistant starch is deliberately delivered to the same place. The two therefore feed one microbial process from different directions. The visible trade-off is gas and bloating in the first week, which usually settles with a slow build.
Supplemental amylase and glucoamylase are added to speed starch breakdown. Mulberry leaf is added to slow it. Taken in the same meal they work against each other and the carbohydrate-moderating intent of the leaf extract is lost. Anyone using a broad digestive enzyme blend should space it from a pre-meal mulberry dose.
Nothing specific on file for Morus Alba. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Morus Alba actually does.
Mulberry leaf carries 1-deoxynojirimycin, a sugar look-alike close enough to glucose to park in the gut's carb-splitting enzymes, so starch gets broken down more slowly and glucose enters the blood more gradually after a starchy meal.
The effect is a competition inside the gut, so the extract has to arrive with or just before the carbs. Taken away from food, there's nothing there to compete with.
Carbohydrate that escapes digestion in the small intestine moves on to the colon, where bacteria ferment it. That's why gas, bloating and loose stools show up first at higher doses. It comes straight from the intended mechanism, not a separate problem.
The leaf also brings flavonol glycosides, mainly rutin and quercetin derivatives, plus chlorogenic acid. These account for the antioxidant profile seen in lab studies and are a different chemical family from the sugar mimics behind the enzyme effect.
Where Morus Alba comes from.
It starts as mulberry leaves from farmed trees. The leaves are dried, soaked to pull out the water-soluble actives, sometimes cleaned up further to concentrate them, tested to confirm how much of the key compound is present, then dried into a powder that goes into capsules.
Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.
Leaves of the white mulberry, mostly from cultivated stands in China, Japan, Korea and India where the tree is also grown for sericulture. Leaf age at harvest changes the iminosugar content.
Dried leaf is milled and extracted with water or a water-ethanol mix. Iminosugars are highly water soluble, so aqueous systems recover them well; higher ethanol fractions pull more flavonols.
Some producers pass the extract over ion-exchange resin to concentrate the basic iminosugar fraction and drop sugars and pigment. Others skip this and sell a lower-percentage extract.
Content is set against a reference standard, usually by HPLC with derivatisation or by LC-MS. Method differences are the main reason two extracts labelled the same can differ.
The concentrate is dried onto maltodextrin or a similar carrier, then blended, encapsulated or tabletted.
Getting Morus Alba from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Pooled trials found mulberry leaf or mulberry leaf extract lowered post-meal and fasting blood glucose readings.Meta-analysis. Cui et al., 2023 (Food & function). PMID 36644880 ↗
- Adding mulberry leaf and corn silk extract to lactose-hydrolysed milk reduced the rise in blood glucose after the drink.Randomised trial. Sun et al., 2025 (Clinical nutrition ESPEN). PMID 40187731 ↗
- Adults with sleep complaints taking mulberry leaf extract with tryptophan reported better sleep quality and better mood on waking than placebo.Randomised trial. Soon et al., 2025 (European journal of nutrition). PMID 40072601 ↗
- Mulberry leaf extract shifted metabolic, inflammatory and oxidative stress markers in the supplemented group; these are laboratory markers, not clinical outcomes.Randomised trial. Taghizadeh et al., 2022 (Clinical Nutrition ESPEN). PMID 35623877 ↗
- The review gathers mechanistic and clinical work on mulberry extract acting on metabolic risk factors and concludes the human evidence base remains early.Narrative review. Yu et al., 2025 (International Journal of Molecular Sciences). PMID 40943306 ↗
- A multi-ingredient supplement containing mulberry-derived material lowered post-meal glucose and insulin readings after a carbohydrate-rich challenge; the effect belongs to the blend, not to any single component.Open-label trial. Venugopal et al., 2024 (Nutrients). PMID 39064681 ↗
- A nutraceutical combination naming mulberry among its components moved both lipid and glucose measures in participants at cardiometabolic risk; the design cannot separate the ingredients.Open-label trial. Pacella et al., 2025 (Cardiovascular Diabetology). PMID 41044582 ↗
- Mulberry leaf supplementation improved glycaemic measures in the model, while no difference was detected in renal or cardiovascular markers, which is a failure to detect rather than evidence of no effect.Animal study. Gryn-Rynko et al., 2026 (Journal of Physiology and Pharmacology). PMID 42272281 ↗
- Preclinical work on berry and mulberry extracts reports antioxidant activity in cardiac tissue models; the findings are mechanistic and do not transfer to people.Animal study. Symeonidi et al., 2026 (Phytotherapy Research). PMID 42215287 ↗
- Selected berry varieties including mulberry acted on oxidative stress and insulin signalling markers in the animal models used; marker changes only.Animal study. Mohammed et al., 2026 (Brain and Behavior). PMID 42015507 ↗
- Feeding Morus alba leaf produced a distinct gut microbial profile compared with an alternative feed; the finding is about the leaf as a feed substrate in an insect species.Animal study. Shafique et al., 2026 (Open Veterinary Journal). PMID 42375244 ↗
These are the studies our verdict leans on, chosen from the 1,512 we read for Morus Alba. The full linked list is below.
The studies, linked.
4 sources behind our Morus Alba verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialComparison of Effectiveness of Morus Alba and Chlorhexidine Gels on Moderate Periodontitis Among 35 to 55 Year Old Subjects: A Hospital Based Randomized Controlled TrialClinicalTrials.gov ↗NA · 180 participants · Completed
- Clinical trialEFFICACY OF MORUS ALBA FRUIT EXTRACTS AND CHLORHEXIDINE ON SALIVARY STREPTOCOCCUS MUTANS AND pH LEVELSClinicalTrials.gov ↗NA · 120 participants · Completed
- Clinical trialEffect of Mulberry Leaf Extract on Glycemic Durability in Non-insulin Dependent Diabetes Mellitus: a Double-blind, Randomized, Placebo-controlled Pilot Study (Mul-DM)ClinicalTrials.gov ↗PHASE2 · 24 participants · Completed
- Clinical trialA 12 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety Morus Alba L. Extract on Improvement of Blood FlowClinicalTrials.gov ↗NA · 100 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 66 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Morus Alba is, not how risky it is. A report is not proof Morus Alba caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.